Cargando…

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis

Detalles Bibliográficos
Autores principales:	Tseng, Chen I., Roddick, Alistair J., Bottomley, Matthew J., Shapiro, Susan, Udayaraj, Udaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928643/ https://www.ncbi.nlm.nih.gov/pubmed/36819183 http://dx.doi.org/10.1002/jha2.606

Ejemplares similares

Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics
por: Peyro-Saint-Paul, Laure, et al.
Publicado: (2023)

Elevated International Normalized Ratio Due to Apixaban in Patient With End-Stage Renal Disease on Hemodialysis
por: Kahlon, Navkirat, et al.
Publicado: (2022)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
por: Badreldin, Hisham A, et al.
Publicado: (2020)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022)

Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy
por: Andrews, Lauren, et al.
Publicado: (2021)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Real-world renal function among patients with multiple myeloma in the United States
por: Mikhael, Joseph, et al.
Publicado: (2021)

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
por: Gaspar, Frédéric, et al.
Publicado: (2023)

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
por: Byon, Wonkyung, et al.
Publicado: (2019)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
por: Herrera, Noelle D., et al.
Publicado: (2021)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023)

Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
por: Wang, Xiaoli, et al.
Publicado: (2013)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Reply to Callahan: Identifying “Real” Patients in the Real World
por: Dempsey, Timothy M.
Publicado: (2020)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Ending support for medical organisations puts the world at risk
por: Baranchuk, Adrian, et al.
Publicado: (2020)

Apixaban successfully resolved a warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis
por: Park, Yae Min, et al.
Publicado: (2019)

Transplant programmes in areas with high SARS-CoV-2 transmission
por: Reddy, Srikanth, et al.
Publicado: (2020)

Decline in platelet function following administration of a snake venom-derived hemocoagulase in a patient with end-stage renal disease
por: Kang, Byung Soo, et al.
Publicado: (2020)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis
por: Murtaza, Ghulam, et al.
Publicado: (2021)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
por: Merali, Samira J., et al.
Publicado: (2023)

Endorsing: closing the loop on diagnostic tests in electronic health care records
por: Wronska, Marta, et al.
Publicado: (2023)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism
por: Chang, Geng-He, et al.
Publicado: (2021)

Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study
por: Ellenbogen, Michael I., et al.
Publicado: (2022)

The contribution of apixaban renal clearance to total clearance
por: Frost, Charles, et al.
Publicado: (2015)

Altered Antibiotic Pharmacokinetics during Extracorporeal Membrane Oxygenation: Cause for Renal Function?
por: Li, Yongnan, et al.
Publicado: (2022)

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
por: Meerveld-Eggink, Aafke, et al.
Publicado: (2022)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kpd2su4d3jiiq1mkc92hjvvnh7